Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil.

Findlay, Michael; Young, Helen; Cunningham, David; Iveson, A.; Cronin, B.; Hickish, Tamas; Pratt, B.; Husband, JE; Flower, M. A.; Ott, R. J.

doi:10.1200/jco.1996.14.3.700

Cited by 285 publications

(92 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Reference standards for the serial 18 F-FDG PET studies were the clinical response data, according to the World Health Organization (WHO) classification. In contrast to the studies of Findlay et al (10) and Bender et al (11), that study investigated absolute standardized uptake values (SUVs) and kinetic parameters and not fractional changes between baseline and follow-up scans. Even the quantitative values from the first PET study (at baseline) were predictive with respect to therapy outcome.…”

Section: Chemotherapy Response Monitoring In Advanced Colorectal Cancermentioning

confidence: 76%

“…Five studies (Table 1) reported the predictive value of 18 F-FDG PET in patients treated with chemotherapy for nonresectable colorectal cancer liver metastases (10)(11)(12)(13)(14). As early as 1996, Findlay et al (10) studied 18 patients before, at 1-2 wk after, and at 4-5 wk after 5-fluorouracil (5-FU) chemotherapy with or without interferon-a by using a nondedicated PET system with a limited resolution.…”

Section: Chemotherapy Response Monitoring In Advanced Colorectal Cancermentioning

confidence: 99%

See 1 more Smart Citation

Monitoring and Predicting Response to Therapy with ¹⁸F-FDG PET in Colorectal Cancer: A Systematic Review

Geus-Oei¹,

Vriens²,

Laarhoven³

et al. 2009

J Nucl Med

196

131

View full text Add to dashboard Cite

Molecular imaging with 18 F-FDG PET has been proven useful in the management of colorectal cancer. 18 F-FDG PET plays a pivotal role in staging before surgical resection of recurrent colorectal cancer and metastases, in the localization of recurrence in patients with an unexplained rise in serum carcinoembryonic antigen levels, and in the assessment of residual masses after treatment. Currently, there is increasing interest in the role of 18 F-FDG PET beyond staging. The technique appears to have significant potential for the characterization of tumors and for the prediction of prognosis in the context of treatment stratification and early assessment of tumor response to therapy. This systematic review provides an overview of the literature on the value of 18 F-FDG PET for monitoring and predicting the response to therapy in colorectal cancer. The review covers chemotherapy response monitoring in advanced colorectal cancer, monitoring of the effects of local ablative therapies, and preoperative radiotherapy and multimodality treatment response evaluation in primary rectal cancer. Given the added value of 18 F-FDG PET for these indications, implementation in clinical practice and systematic inclusion in therapeutic trials to exploit the potential of 18 F-FDG PET are warranted.

show abstract

Section: Chemotherapy Response Monitoring In Advanced Colorectal Cancermentioning

confidence: 76%

Section: Chemotherapy Response Monitoring In Advanced Colorectal Cancermentioning

confidence: 99%

Monitoring and Predicting Response to Therapy with ¹⁸F-FDG PET in Colorectal Cancer: A Systematic Review

Geus-Oei¹,

Vriens²,

Laarhoven³

et al. 2009

J Nucl Med

196

131

View full text Add to dashboard Cite

show abstract

“…FDG-PET has high sensitivity for colorectal cancer recurrence (230) and has particular utility in assessing the response in colorectal patients with hepatic metastases. For example, response to 5-FU with or without IFN was associated with lower FDG-PET SUVs at 4 to 5 weeks or with lower tumor/liver ratios at 1 to 2 or 4 to 5 weeks (227). Similarly, FDG-PET identified patients responsive to combination therapy with 5-FU and folinic acid (231) …”

Section: Fdg-pet In Oncologic Drug Developmentmentioning

confidence: 99%

Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development

Kelloff

Hoffman

Johnson

et al. 2005

Clinical Cancer Research

598

382

View full text Add to dashboard Cite

2-[ 18 F]Fluoro-2-deoxyglucose positron emission tomography (FDG-PET) assesses a fundamentalpropertyof neoplasia, theWarburgeffect.This molecularimaging technique offers acomplementary approach to anatomic imaging that is more sensitive and specific in certain cancers. FDG-PET has been widely applied in oncology primarily as a staging and restaging tool that can guide patient care. However, because it accurately detects recurrent or residual disease, FDG-PETalso has significant potential for assessing therapy response. In this regard, it canimprove patient management by identifying responders early, before tumor size is reduced; nonresponders could discontinue futile therapy. Moreover, a reductioninthe FDG-PETsignal withindays or weeks of initiating therapy (e.g., in lymphoma, non^small cell lung, and esophageal cancer) significantly correlates with prolonged survival and other clinical end points now usedin drug approvals.These findings suggest that FDGPETcould facilitate drug development as an early surrogate of clinicalbenefit.This article reviews the scientificbasis ofFDG-PETandits development andapplicationasavaluableoncologyimagingtool. Its potential to facilitate drug development in seven oncologic settings (lung, lymphoma, breast, prostate, sarcoma, colorectal, and ovary) is addressed. Recommendations include initial validation against approved therapies, retrospective analyses to define the magnitude of change indicative of response, further prospective validation as a surrogate of clinical benefit, and application as a phase II/III trial end point to accelerate evaluation and approval of novel regimens and therapies. FDG-PET (2-[18 F]Fluoro-2-deoxyglucose positron emission tomography) is an accepted and widely used clinical imaging tool in oncology. U.S. Medicare reimbursement of FDG-PET recently expanded to encompass all cancer patients participating in certain prospective studies or registries in addition to more general coverage in 10 defined oncologic settings. Primarily covered are disease diagnosis, staging, and restaging, but FDG-PET is also approved for monitoring response to therapy in locally advanced and metastatic breast cancers when a change in therapy is anticipated. Clinical trials in breast cancer and other settings [e.g., non -small cell lung cancer (NSCLC) and esophageal cancer] have shown that FDG-PET imaging can provide an early indication of therapeutic response that is well correlated with clinical outcome. FDG-PET thus has the potential to improve patient management, particularly by signaling the need for early therapeutic changes in nonresponders, thereby obviating the side effects and costs of ineffective treatment. As an early surrogate for clinical benefit, the modality also has the potential to facilitate oncologic drug development by shortening phase II trials and detecting clinical benefit earlier in phase III investigations. Studies to further explore and validate these approaches are needed and can be conducted in parallel with those employing end points now use...

show abstract

“…8,9 In addition to the detection of hypermetabolic tumor, effective suppression early in the course of therapy has been linked to superior patient outcome in lymphoma and a variety of epithelial cancers. [10][11][12][13][14][15][16][17][18][19][20] When combined with CT, FDG uptake can be readily localized anatomically and, in the case of myeloma, hypermetabolic activity in intramedullary and extramedullary sites distinguished and osteolytic bone destruction recognized. 21 As part of Total Therapy 3 (see "Total Therapy 3 program"), we prospectively examined the prognostic implications of FDG-PET/CT and MRI in patients with newly diagnosed myeloma.…”

Section: Introductionmentioning

confidence: 99%

F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma

Bartel

Haessler

Brown

et al. 2009

Blood

465

358

View full text Add to dashboard Cite

F18-fluorodeoxyglucose positron emission tomography (FDG-PET) is a powerful tool to investigate the role of tumor metabolic activity and its suppression by therapy for cancer survival. As part of Total Therapy 3 for newly diagnosed multiple myeloma, metastatic bone survey, magnetic resonance imaging, and FDG-PET scanning were evaluated in 239 untreated patients. All 3 imaging techniques showed correlations with prognostically relevant baseline parameters: the number of focal lesions (FLs), especially when FDG-avid by PET-computed tomography, was positively linked to high levels of ␤-2-microglobulin, C-reactive protein, and lactate dehydrogenase; among gene expression profiling parameters, high-risk and proliferation-related parameters were positively and low-bone-disease molecular subtype inversely correlated with FL. The presence of more than 3 FDG-avid FLs, related to fundamental features of myeloma biology and genomics, was the leading independent parameter associated with inferior overall and event-free survival. Complete FDG suppression in FL before first transplantation conferred significantly better outcomes and was only opposed by gene expression profilingdefined high-risk status, which together accounted for approximately 50% of survival variability (R 2 test). Our results provide a rationale for testing the hypothesis that myeloma survival can be improved by altering treatment in patients in whom FDG suppression cannot be achieved after induction

show abstract

Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil.

Abstract: Positron emission tomography used to evaluate the uptake of FDG in tumors yields data that correlate with the antitumor effect of chemotherapy in patients with liver metastases from colorectal cancer.

Cited by 285 publications

References 5 publications

Monitoring and Predicting Response to Therapy with ¹⁸F-FDG PET in Colorectal Cancer: A Systematic Review

Monitoring and Predicting Response to Therapy with ¹⁸F-FDG PET in Colorectal Cancer: A Systematic Review

Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development

F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma

Contact Info

Product

Resources

About

Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil.

Abstract: Positron emission tomography used to evaluate the uptake of FDG in tumors yields data that correlate with the antitumor effect of chemotherapy in patients with liver metastases from colorectal cancer.

Cited by 285 publications

References 5 publications

Monitoring and Predicting Response to Therapy with 18F-FDG PET in Colorectal Cancer: A Systematic Review

Monitoring and Predicting Response to Therapy with 18F-FDG PET in Colorectal Cancer: A Systematic Review

Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development

F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma

Contact Info

Product

Resources

About

Monitoring and Predicting Response to Therapy with ¹⁸F-FDG PET in Colorectal Cancer: A Systematic Review

Monitoring and Predicting Response to Therapy with ¹⁸F-FDG PET in Colorectal Cancer: A Systematic Review